Hellenic Cooperative Oncology Group

Recent papers from Hellenic Cooperative Oncology Group

1. HeCOG Cancer Biobank and Registry: a nationwide real-world resource for translational oncology researchESMO Real World Data and Digital Oncology · 2026
2. DFLEX: A Blockchain-Anchored Marketplace for Direct Participation of Small Distributed Energy Resources in Transmission and Distribution System Operator Flexibility Markets—Evidence from a One-Year Island PilotEnergies · 2026
3. Atmospheric Forcing on Solar Energy in Complex Terrain: A Digital Twin Assessment in an Intermontane Basin in Southern BalkansAtmosphere · 2026
4. Prospective-retrospective HeCOG phase III trial validation of Polaris TME for the prediction of TILs from whole-slide images in high-risk early breast cancer.Journal of Clinical Oncology · 2026
5. Abstract 1448: Deep learning integration of molecular and histopathological data for prognostic stratification in non small cell lung cancer.Cancer Research · 2026
6. Abstract PS4-01-20: Clinico-pathological and genomic features of HER2-low early Breast Cancer (eBC). Results of retrospective analysis of seven adjuvant trials by the Hellenic Cooperative Oncology Group (HeCOG)Clinical Cancer Research · 2026
7. Abstract PS4-02-18: Detection of germline and somatic pathogenic variants in patients with de novo metastatic breast cancer (dnMBC) and assessment of their prognostic relevance: A Hellenic Cooperative Oncology Group (HeCOG) translational cohort studyClinical Cancer Research · 2026
8. Real-World Toxicity and Effectiveness Study of Abemaciclib in Greek Patients with Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: A Multi-Institutional StudyCancers · 2025
9. Intercalated Avelumab plus platinum-based chemotherapy in patients with Extensive-Stage Small-Cell Lung cancer (PAVE): Final outcome, immunophenotypic and biomarker analysis of a multi-center phase II Hellenic Cooperative Oncology Group studyEuropean Journal of Cancer · 2025
10. From ancient wisdom to modern practices: transformative potential of digital health innovations in advancing traditional medicineJournal of Complementary and Integrative Medicine · 2025
11. Enhancing socio-emotional learning and mental health through computational thinking: a cross-cultural analysis of the COMPUSEL programmeFrontiers in Psychology · 2025
12. Evaluating Source Complexity in Blended Milk Cheese: Integrated Strontium Isotope and Multi-Elemental Approach to PDO Graviera NaxosFoods · 2024
13. Real-world efficacy and toxicity data of paclitaxel and ramucirumab compared with other treatment regimens in patients with advanced gastric cancerESMO Gastrointestinal Oncology · 2024
14. Safety and tolerability of durvalumab + carboplatin/paclitaxel followed by durvalumab ± olaparib in patients with newly diagnosed advanced or recurrent endometrial cancer (EC) in the DUO-E/GOG-3041/ENGOT-EN10 trial.Journal of Clinical Oncology · 2024
15. 40MO First-line (1L) durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib for endometrial cancer (EC) (DUO-E): Objective response rate (ORR), duration of response (DoR) and time to treatment discontinuation or death (TDT) by mismatch repair (MMR) statusESMO Open · 2024
16. 146P Long-term outcomes of patients with triple-negative breast cancer treated with adjuvant dose-dense sequential chemotherapy (ddsc): A Hellenic Cooperative Oncology Group (HeCOG) studyESMO Open · 2024
17. 197MO Final outcome, immunophenotypic and biomarker analysis of intercalated avelumab plus platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (PAVE): A pilot phase II study of the Hellenic co-operative oncology groupESMO Open · 2024
18. Fava Santorinis: Brining Added Value to a Protected Designation of Origin (PDO) Product through the Security of the Traditional Cultivar and Farmers NetworkMDPI · 2024
19. The Mutographs biorepository: A unique genomic resource to study cancer around the worldCell Genomics · 2024
20. Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytesThe Breast · 2023